No new sites of disease should be observed. Revised Protocol No.: 04 Date: 31-May-2019 190 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS 7. FDG: a) Typically FDG-avid lymphoma: for patients without a pre-tr eatment PET scan or if the pre-treatment PET scan was positive, the post-treatment PET scan should be positive in at least 1 previously involved site. b) Variably FDG-avid lymphomas/FDG avidity unknown: for patients without a pre-treatment PET scan, or if a pre-treatment PET scan was negative, CT criteria s hould be used. In patients with follicular lymphoma or mantle-cell lymphoma, a PET scan is only indicated with 1 or at most 2 residual masses that have regressed by > 50% on CT; those with more than 2 residual lesions are unlikely to be PET negative and should be considered partial responders. SD (Stable Disease) 1.